Evidence map›Paper›PMID 32952493›Full record

ArticleAdvanced functional materials2020

Biomaterials functionalized with MSC secreted extracellular vesicles and soluble factors for tissue regeneration.

Meadhbh Á Brennan, Pierre Layrolle, David J Mooney

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced functional materials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 196 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
196citing papers in PubMed, 3 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

196 citing papers in PubMed, 3 syntheses or guidelines pooled it, 382 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. PEBP1 Regulates Ferroptosis in Acute Glaucoma: Targeted Therapy Using Engineered Exosomes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

136 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Meadhbh Á BrennanJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Pierre LayrolleINSERM, UMR 1238, PHY-OS, Bone sarcomas and remodeling of calcified tissues, Faculty of Medicine, University of Nantes, Nantes, France.
David J MooneyJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Nantes Université · FRHarvard University · US

Funding

POLYMERIC MATRICES WITH DEFINED CELL ADHESION AND MECHANR01DE013033 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOONEY, DAVID J · 1998 to 2018
$3.0M
NIDCR NIH HHS R01 DE013033
6 · The paper itself

Abstract

The therapeutic benefits of mesenchymal stromal cell (MSC) transplantation have been attributed to their secreted factors, including extracellular vesicles (EVs) and soluble factors. The potential of employing the MSC secretome as an alternative acellular approach to cell therapy is being investigated in various tissue injury indications, but EVs administered via bolus injections are rapidly sequestered and cleared. However, biomaterials offer delivery platforms to enhance EV retention rates and healing efficacy. In this review, we highlight the mechanisms underpinning the therapeutic effects of MSC-EVs and soluble factors as effectors of immunomodulation and tissue regeneration, conferred primarily via their nucleic acid and protein contents. We discuss how manipulating the cell culture microenvironment or genetic modification of MSCs can further augment the potency of their secretions. The most recent advances in the development of EV-functionalized biomaterials that mediate enhanced angiogenesis and cell survival, while attenuating inflammation and fibrosis, are presented. Finally, some technical challenges to be considered for the clinical translation of biomaterials carrying MSC-secreted bioactive cargo are discussed.

Indexed as

exosomesExtracellular vesiclesfunctionalized biomaterialshydrogelsmesenchymal stromal cellstissue regeneration

Identifiers

PMID32952493
PMCPMC7494127
OpenAlexW3011097693

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.